RabbitMap
← Directory

Scientific controversy

Vaccine–autism linkAtlas

Health & Medicine · Vaccines & immunization

Competing accounts of whether routine childhood vaccines contribute to autism diagnoses, weighing large epidemiologic comparisons against subgroup and timing-based clinical claims.

Open the case

Evidence

16 cited sources · both-sides readings on each item

  • CDC autism and vaccines

    CDC · primary

    • Pos A · Read as summarizing agency position that studies do not support a vaccine-autism causal link.“autism”
    • Pos B · Read as an institutional summary that link accounts treat as incomplete on subgroup schedules.“autism”
    • Pos A · Read as endorsing epidemiologic assessment pathways.“autism”
    • Pos B · Read as prioritizing averages over case-series signals.“autism”
  • National Academies

    National Academies · secondary

    • Pos A · Read as a major evidence-review tradition on immunization safety questions.“immunization”
    • Pos B · Read as review architecture that critics say sets high bars against detecting subgroup harms.“immunization”
    • Pos A · Read as methods authority for population comparisons.“immunization”
    • Pos B · Read as constraining case-series weight.“immunization”
  • PubMed

    NLM · primary

    • Pos A · Read as an index to large null and related epidemiologic papers.“vaccine autism”
    • Pos B · Read as also containing dissenting case reports and critique papers cited by link accounts.“vaccine autism”
    • Pos A · Read as corpus for methods debates.“vaccine autism”
    • Pos B · Read as corpus for subgroup and chronology claims.“vaccine autism”
  • Full text of "The status of research into Vaccine Safety and Autism (2002)"

    archive.org · secondary

    • Pos A · This 2002 archive compilation is treated as documenting early agency-oriented reviews in which childhood vaccine and autism comparisons are read as showing similar diagnosis rates across groups, with schedule-wide average effects cast as hard to reconcile with multi-year clinical claims the tables summarize.“status of research into Vaccine Safety and Autism”
    • Pos B · This 2002 archive compilation is treated as documenting early safety-status reviews in which childhood vaccine and autism materials are read as leaving clustered diagnosis timing near schedule windows open, with population-average nulls cast as compatible with multi-year clinical patterns the tables summarize.“The status of research into Vaccine Safety”
    • Pos A · Methods discussion within this 2002 research-status text is treated as privileging population comparisons when average vaccine-outcome claims are at issue, with case chronologies cast as thinner designs wherever denominators and base rates dominate the review corpus.“research into Vaccine Safety and Autism (2002)”
    • Pos B · Methods discussion within this 2002 research-status text is treated as under-weighting case chronologies when subset timing probes are at issue, with population nulls cast as thinner designs wherever uncommon schedule clusters dominate the review corpus.“Vaccine Safety and Autism (2002)”
  • Autism and Vaccines

    cdc.gov · primary

    • Pos A · Methods cues on this page are treated as privileging population comparisons for average vaccine-autism claims, with case chronologies cast as thinner designs when denominators and base rates are the main question in the review corpus.“quality, objectivity, utility, and integrity of information”
    • Pos A · Agency material on this page is read as showing that childhood vaccines track with similar autism diagnosis rates across vaccination-status groups, with large schedule-wide effects treated as incompatible with multi-year clinical patterns those cohort tables summarize.“Vaccines do not cause Autism”
    • Pos B · Agency material on this page is read as still leaving clustered autism diagnosis rates near vaccination-schedule windows under discussion, with average population-null effects treated as compatible with multi-year clinical patterns those cohort tables summarize.“studies have not ruled out the possibility”
    • Pos B · Methods cues on this page are treated as under-weighting case chronologies for subset vaccine-autism probes, with population nulls cast as thinner designs when uncommon timing clusters are the main question in the review corpus.“plausible biologic mechanisms and potential causal links”
  • Vaccines and autism

    chop.edu · primary

    • Pos A · The CHOP page is read as showing cited MMR-autism papers fail basic checks, so agency cohort tables remain treated as evidence of similar diagnosis rates across vaccination-status groups and large schedule-wide effects stay cast as incompatible with the multi-year patterns those tables summarize.“Both studies are critically flawed”
    • Pos B · The CHOP page is read as narrowing critique to two older papers only, so agency cohort tables remain treated as still compatible with clustered diagnosis rates near schedule windows and average population-null findings stay cast as leaving multi-year clinical patterns unaddressed.“Two studies have been cited by those”
    • Pos A · The CHOP safety overview is treated as privileging population comparisons when it flags source studies as flawed, so case chronologies are cast as thinner designs whenever denominators and base rates are the main question in the surrounding review corpus.“Autism has been studied for decades”
    • Pos B · The CHOP safety overview is treated as under-weighting case chronologies when it flags source studies as flawed, so population nulls are cast as thinner designs whenever uncommon timing clusters are the main question in the surrounding review corpus.“claiming that the MMR vaccine causes autism”
  • Burlison Leads Effort to Investigate National Academies Over Taxpayer Funding Concerns

    burlison.house.gov · primary

    • Pos A · The funding-review letter is read as a process critique that leaves agency cohort tables on vaccines and autism still treated as showing similar diagnosis rates across vaccination-status groups, with large schedule-wide null summaries cast as hard to square with claimed multi-year clinical patterns.“concerns about bias, conflicts of interest”
    • Pos B · The funding-review letter is read as a process critique that weakens confidence in agency cohort tables on vaccines and autism, with average population-null summaries cast as still compatible with diagnosis clustering near schedule windows those tables report. The competing reading remains available for comparison from the same public materials.“blur the line between research and advocacy”
    • Pos A · Methods guidance tied to federally backed reviews is treated as still privileging population comparisons for average vaccine-outcome claims, with case chronologies cast as thinner when denominators and base rates remain the main review question despite funding-bias disputes.“provide independent scientific analysis”
    • Pos B · Methods guidance tied to federally backed reviews is treated as still under-weighting case chronologies for subset timing probes, with population nulls cast as thinner when uncommon clusters remain the main review question amid funding-bias disputes.“driven by advocacy, it can be used”
  • The autism-vaccine story: fiction and deception?

    pmc.ncbi.nlm.nih.gov · primary

    • Pos A · The cohort and case-control comparisons are read as showing similar autism diagnosis rates across MMR vaccination status, with the summarized null findings treated as incompatible with schedule-wide causal effects large enough to drive multi-year clinical patterns.“no association between MMR vaccination and autism”
    • Pos B · The cohort and case-control comparisons are read as reporting average population-null autism results that remain compatible with multi-year timing-clustered clinical patterns, with schedule-window diagnosis clustering treated as not fully ruled out by those table-level summaries.“no association between MMR vaccination and autism”
    • Pos A · The review's emphasis on large cohort and case-control designs is treated as privileging population comparisons for average vaccine-outcome claims, with smaller case chronologies cast as thinner when denominators and base rates are the main question.“at least 20 higher-quality studies”
    • Pos B · The review's emphasis on large cohort and case-control designs is treated as under-weighting case chronologies for subset timing probes, with population null summaries cast as thinner when uncommon schedule-window clusters are the main question.“at least 20 higher-quality studies”
  • Do Vaccines Cause Autism? – Institute for Vaccine Safety

    vaccinesafety.edu · primary

    • Pos A · The safety-institute summary is read as aligning agency-scale cohort patterns with similar autism diagnosis rates across childhood vaccination-status groups, and its IOM-cited rejection of MMR and thimerosal causal links is treated as reinforcing that large schedule-wide nulls sit uneasily beside multi-year clinical timing claims the same tables already aggregate.“Childhood vaccines do not cause autism”
    • Pos B · The safety-institute summary is read as restating average population-null conclusions while still recording the original case series’ parent-reported behavioral onsets near MMR doses, and those schedule-window clusters are treated as remaining compatible with multi-year clinical patterns that broad cohort averages can leave unresolved. The competing reading remains available for comparison from the same public materials.“behavioral issues temporally associated with MMR vaccination”
    • Pos A · Methods language on the page is treated as privileging the IOM’s body-of-evidence population comparisons when average causal claims are under review, and the small retrospective case series is cast as a thinner design once denominators and base rates become the central question in the cited corpus.“body of evidence favors rejection of a causal relationship”
    • Pos B · Methods language on the page is treated as under-weighting the same case chronologies when uncommon timing subsets are the probe of interest, and the population-level null summaries are cast as thinner designs once schedule-window clusters rather than overall averages become the central question in the cited corpus.“12 children with pervasive developmental disorder”
  • After unprecedented autism-vaccine messaging change, scientists, advocates say CDC no longer trustworthy

    cidrap.umn.edu · primary

    • Pos A · The CDC messaging shift is cited as a break from prior summaries of cohort tables that are read as showing similar autism diagnosis rates across vaccination groups, with advocates treating the new wording as incompatible with those large-scale patterns.“Studies have shown that there is no link”
    • Pos B · The CDC messaging shift is cited as aligning with readings of cohort tables that are treated as leaving room for clustered timing patterns near schedule windows, with the new wording read as compatible with limits those tables leave open.“studies have not ruled out the possibility”
    • Pos A · Reports on the CDC wording change are read as reinforcing methods guidance that privileges population comparisons for average claims, with specialist commentary treated as casting case chronologies as thinner designs when base rates guide the review corpus.“scientists, advocates say CDC no longer trustworthy”
    • Pos B · Reports on the CDC wording change are read as reinforcing methods guidance that under-weights case chronologies for subset probes, with the revised claim treated as casting population nulls as thinner designs when uncommon timing clusters guide the review corpus.“not an evidence-based claim because studies have not”
  • Autism and Vaccines | Vaccine Safety | CDC

    web.archive.org · primary

    • Pos A · The CDC page is cited as summarizing cohort and antigen-exposure comparisons in which diagnosis rates align across higher and lower vaccine-related exposures, which is read as indicating that schedule-wide effects large enough to drive clinical autism patterns would have appeared in those summaries.“Vaccines do not cause autism”
    • Pos B · The CDC page is cited as summarizing cohort and antigen-exposure comparisons that report average null associations across groups, which is read as still compatible with timing-clustered clinical patterns if those averages smooth over schedule-window subgroups the tables do not resolve.“studies have shown that there is no link”
    • Pos A · Methods framing on the CDC page is treated as elevating large comparison studies of antigens and schedules for average risk questions, with the stated absence of a link cast as following when population denominators organize the review.“A CDC study published in 2013 added”
    • Pos B · Methods framing on the CDC page is treated as elevating large comparison studies while leaving case-timing probes secondary, with the stated absence of a link cast as following when uncommon schedule-window clusters are not the organizing question.“no link between receiving vaccines and developing”
  • Autism-and-Vaccines-_-Vaccine-Safety-_-CDC-Published-12.30.2024-printed-9.23.2025.pdf

    autismdelaware.org · secondary

    • Pos A · CDC key-point summaries are cited as showing agency cohort and multi-study comparisons with similar ASD diagnosis rates across vaccination-status groups, so large schedule-wide causal effects are treated as incompatible with the multi-year clinical patterns those tables are read as summarizing.“there is no link between receiving vaccines and developing”
    • Pos B · CDC key-point summaries are cited as restating population-average nulls from agency cohort tables, while clustered diagnoses near schedule windows are still treated as compatible with multi-year clinical patterns those same tables are read as leaving open at subset scale.“Studies have shown that there is no link”
    • Pos A · Methods framing in the CDC review corpus is treated as privileging population epidemiologic comparisons for average vaccine–ASD claims, with case chronologies cast as thinner designs when denominators and base rates are read as the main question the cited studies address.“No links have been found between any vaccine ingredients”
    • Pos B · Methods framing in the CDC review corpus is treated as under-weighting case chronologies for subset and timing probes, with population nulls cast as thinner designs when uncommon schedule-window clusters are read as the main question the cited studies leave unresolved.“the evidence favors rejection of a causal relationship”
  • Measles Vaccine: No Autism Link

    web.archive.org · secondary

    • Pos A · The archived report is cited as showing laboratory and clinical comparisons in which children with autism lacked measles-virus abnormalities after MMR, treated as aligning with cohort tables that find similar autism diagnosis rates across vaccination-status groups.“Measles Vaccine: No Autism Link”
    • Pos B · The archived report is read as testing average viral persistence rather than diagnosis timing near schedule windows, treated as leaving intact clinical patterns in which clustered onsets remain compatible with null population summaries.“rejected any link between MMR vaccination and autism”
    • Pos A · Methods notes in the coverage are treated as privileging controlled comparisons of viral markers across groups, with the case-series origin of the earlier claim cast as a thinner basis when base-rate questions dominate the review framing.“no abnormalities From MMR Vaccine”
    • Pos B · Methods notes in the coverage are treated as under-weighting chronological case detail around vaccination windows, with group-average viral assays cast as a thinner basis when uncommon timing clusters remain the focal review question.“The measles vaccine doesn't cause long-lasting measles infection”
  • Autism and Vaccines

    restoredcdc.org · primary

    • Pos A · Agency statements on this page are read as summarizing cohort tables that show similar autism diagnosis rates across vaccination-status groups, with the reported absence of links treated as incompatible with large schedule-wide effects over multi-year patterns.“there is no link between receiving vaccines and developing”
    • Pos B · Agency statements on this page are read as summarizing cohort tables that average over diagnosis clusters near vaccination-schedule windows, with the reported population nulls treated as compatible with multi-year clinical patterns those averages can miss.“Vaccines do not cause autism”
    • Pos A · This page's emphasis on epidemiologic studies is treated as privileging population comparisons for average vaccine-outcome claims, with case chronologies cast as thinner designs when denominators and base rates are the main question.“Studies have shown that there is no link”
    • Pos B · This page's emphasis on epidemiologic studies is treated as under-weighting case chronologies for subset timing probes, with population nulls cast as thinner designs when uncommon clusters are the main question.“No links have been found between any vaccine ingredients”
  • MMR vaccine and autism - Wikipedia

    en.wikipedia.org · secondary

    • Pos A · The Wikipedia entry is read as summarizing research that treats large epidemiologic comparisons as showing no elevated autism rates tied to MMR, with the page structure cited as organizing background litigation and media episodes around that population-level reading.“False claims of a link between the MMR vaccine and autism”
    • Pos B · The Wikipedia entry is read as summarizing institutional framing that treats average null findings as decisive, with the page structure cited as organizing clinical timing reports and litigation under a consensus label those multi-year patterns can still sit beside.“Part of a series on Alternative medicine”
    • Pos A · The page's research and background sections are treated as centering large-study summaries over case series, with litigation subsections cited as secondary to the epidemiologic corpus when average effects are the review focus.“MMR vaccine and autism”
    • Pos B · The page's research and background sections are treated as centering population nulls over timing chronologies, with litigation subsections cited as carrying subset signals when uncommon clusters are the review focus.“1998 The Lancet paper”
  • World Health Organization

    WHO · primary

    • Pos A · Read as aligning with large-study safety syntheses used by member states.“vaccine”
    • Pos B · Read as a global consensus node that dissenters say narrows allowable questions.“vaccine”
    • Pos A · Read as supporting standardized epidemiologic methods.“vaccine”
    • Pos B · Read as under-weighting clinical chronologies.“vaccine”

Next: sources →